CEFTRIAXONE BLOCKS THE POLYMERIZATION OF Α-SYNUCLEIN AND EXERTS NEUROPROTECTIVE EFFECTS IN VITRO
Main Article Content
Abstract
The β-lactam antibiotic ceftriaxone was suggested as a therapeutic agent in several neurodegenerative disorders, either for its ability to counteract glutamate-mediated toxicity, as in cerebral ischemia, or for its ability to enhance the degradation of misfolded proteins, as in Alexander’s disease. Recently, the efficacy of ceftriaxone in neuroprotection of dopaminergic neurons in a rat model of Parkinson’s disease was documented. However, which characteristics of ceftriaxone mediate its therapeutic effects remains unclear. Since, at the molecular level, neuronal α-synuclein inclusions and pathological α-synuclein transmission play a leading role in initiation of Parkinson-like neurodegeneration, we thought of investigating, by circular dichroism spectroscopy, the capability of ceftriaxone to interact with α- synuclein. We found that ceftriaxone binds with good affinity to α-synuclein and blocks its in vitro polymerization. Considering this finding, we also documented that ceftriaxone exerts neuroprotective action in an in vitro model of Parkinson’s disease. Our data, in addition to the findings on neuroprotective activity of ceftriaxone on Parkinson-like neurodegeneration in vivo, indicates ceftriaxone as a potential agent in treatment of Parkinson’s disease.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
TURCOMAT publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
References
Nau, R., Prange, H. W., Muth, P., Mahr,
G., Menck, S., Kolenda, H., and Sorgel,
F. (1993) Passage of cefotaxime and
ceftriaxone into cerebrospinal-fluid of
patients with uninflamed meninges.
Antimicrob. Agents Chemother. 37,
−1524.
Rothstein, J. D., Patel, S., Regan, M. R.,
Haenggeli, C., Huang, Y. H., Bergles, D.
E., Jin, L., Hoberg, M. D., Vidensky, S.,
Chung, D. S., Toan, S. V., Bruijn, L. I.,
Su, Z. Z., Gupta, P., and Fisher, P. B.
(2005) β-Lactam antibiotics offer
neuroprotection by increasing glutamate
transporter expression. Nature 433,
−77.
Bachetti, T., Di Zanni, E., Balbi, P.,
Bocca, P., Prigione, I., Deiana, G. A.,
Rezzani, A., Ceccherini, I., and Sechi, G.
(2010) In vitro treatments with
ceftriaxone promote elimination of
mutant glial fibrillary acidic protein and
transcription down-regulation. Exp. Cell
Res. 316, 2152−2165.
Sechi, G., Matta, M., Deiana, G. A.,
Balbi, P., Bachetti, T., Di Zanni, E.,
Ceccherini, I., and Serra, A. (2010)
Ceftriaxone has a therapeutic role in
Alexander disease. Prog. NeuroPsychopharmacol. Biol. Psychiatry 34,
−417.
Sechi, G. P., Ceccherini, I., Bachetti, T.,
Deiana, G. A., Sechi, E., and Balbi, P.
(2013) Ceftriaxone for Alexander’s
disease: a four-year follow-up. JIMD
Rep. 9, 67−71.
Leung, T. C. H., Lui, C. N. P., Chen, L.
W., Yung, W. H., Chan, Y. S., and Yung,
K. K. L. (2012) Ceftriaxone ameliorates
motor deficits and protects dopaminergic
neurons in 6-hydroxydopamine-lesioned
rats. ACS Chem. Neurosci. 3, 22−30.
Ozansoy, M., and Basak, A. N. (2012)
The central theme of Parkinson’s disease:
α-synuclein. Mol. Neurobiol. 47,
−465.
Sechi, G., Balbi, P., Bachetti, T., and
Ceccherini, I. (2011) Safe drugs to fight
mutant protein overload and α-1-
antitrypsin deficiency. J. Hepatol. 55,
−950.
Spillantini, M. G., Schmidt, M. L., Lee,
V. M. Y., Trojanowski, J. Q., Jakes, R.,
and Goedert, M. (1997) α -Synuclein in
Lewy bodies. Nature 388, 839−840.
Luk, K. C., Kehm, V., Carroll, J., Zhang,
B., O’Brien, P., Trojanowski, J. Q., and
Lee, V. M. Y. (2012) Pathological α –
synuclein transmission initiates
Parkinson-like neurodegeneration in
nontransgenic mice. Science 338,
−953.
Grau, C. M., and Greene, L. A. (2012)
Use of PC12 cells and rat superior
cervical ganglion sympathetic neurons as
models for neuroprotective assays
relevant to Parkinson’s disease. In
Neurotrophic Factors: Methods and
Protocols (Series: Methods in Molecular
Biology), Vol. 846, pp 201−211,
Springer, New York.
Bartolini, M., Bertucci, C., Bolognesi, M.
L., Cavalli, A., Melchiorre, C., and
Andrisano, V. (2007) Insight into the
kinetic of amyloid β(1−42) peptide selfaggregation: Elucidation of inhibitors’
mechanism of action. ChemBioChem 8,
−2161.
Smith, N. W., Annunziata, O., and
Dzyuba, S. V. (2009) Amphotericin B
interactions with soluble oligomers of
amyloid A beta 1−42 peptide. Bioorg.
Med. Chem. 17, 2366−2370.
Marchiani, A., Mammi, S., Siligardi, G.,
Hussain, R., Tessari, I., Bubacco, L.,
Delogu, G., Fabbri, D., Dettori Maria, A.,
Sanna, D., Dedola, S., Serra Pier, A., and
Ruzza, P. (2013) Small molecules
interacting with α-synuclein:
antiaggregating and cytoprotective
properties. Amino Acids 45, 327−338.
Huang, C. Y. (1982) Determination of
binding stoichiometry by the continuous
variation method: the Job plot. Methods
Enzymol. 87, 509−525.